Cargando…

Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors

COVID-19, caused by the highly transmissible severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has rapidly spread and become a pandemic since its outbreak in 2019. We have previously discovered that aloperine is a new privileged scaffold that can be modified to become a specific antivira...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Li, Zhu, Lei, Xie, Hua, Goodwin, Jeffery Shawn, Rana, Tanu, Xie, Lan, Chen, Chin-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455918/ https://www.ncbi.nlm.nih.gov/pubmed/36077056 http://dx.doi.org/10.3390/ijms23179659

Ejemplares similares

Identification of SARS-CoV-2 entry inhibitors among already approved drugs
por: Yang, Li, et al.
Publicado: (2020)

Indolizidines and quinolizidines: natural products and beyond
por: Michael, Joseph P
Publicado: (2007)

Peptide and peptide-based inhibitors of SARS-CoV-2 entry
por: Schütz, Desiree, et al.
Publicado: (2020)

Screening of Natural Products Inhibitors of SARS-CoV-2 Entry
por: González-Maldonado, Pamela, et al.
Publicado: (2022)

Cell entry by SARS-CoV-2
por: Peng, Ruchao, et al.
Publicado: (2021)

Clotting and SARS-CoV-2 entry
por: Hofer, Ursula
Publicado: (2022)

Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
por: Tasso, Bruno, et al.
Publicado: (2023)

Quinolizidine-Type Alkaloids: Chemodiversity, Occurrence, and Bioactivity
por: Cely-Veloza, Willy, et al.
Publicado: (2023)

Identification of potent small molecule inhibitors of SARS-CoV-2 entry
por: Mediouni, Sonia, et al.
Publicado: (2022)

Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry
por: Wang, Haofeng, et al.
Publicado: (2023)

Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products
por: He, Chang-Long, et al.
Publicado: (2021)

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor
por: Han, Dong P., et al.
Publicado: (2006)

Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2
por: Liu, Ke, et al.
Publicado: (2020)

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
por: Acharya, Arpan, et al.
Publicado: (2021)

Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022)

Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective
por: Risener, Caitlin J., et al.
Publicado: (2023)

Cell entry mechanisms of SARS-CoV-2
por: Shang, Jian, et al.
Publicado: (2020)

SARS-CoV-2, Early Entry Events
por: Chambers, James P., et al.
Publicado: (2020)

Mechanisms of SARS-CoV-2 entry into cells
por: Jackson, Cody B., et al.
Publicado: (2021)

ETM-ANN Approach Application for Thiobenzamide and Quinolizidine Derivatives
por: Saracoglu, M., et al.
Publicado: (2010)

Quinolizidine alkaloid biosynthesis: recent advances and future prospects
por: Bunsupa, Somnuk, et al.
Publicado: (2012)

Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors
por: Ma, Ling, et al.
Publicado: (2023)

Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV
por: V. K., Priya, et al.
Publicado: (2021)

The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
por: Ahmad, Iqrar, et al.
Publicado: (2021)

SELEX based aptamers with diagnostic and entry inhibitor therapeutic potential for SARS-CoV-2
por: Halder, Sayanti, et al.
Publicado: (2023)

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
por: Ou, Xiuyuan, et al.
Publicado: (2020)

Surface vimentin is critical for the cell entry of SARS-CoV
por: Yu, Yvonne Ting-Chun, et al.
Publicado: (2016)

Tumor markers as an entry for SARS‐CoV‐2 infection?
por: Xia, Pu, et al.
Publicado: (2020)

Entry, egress and vertical transmission of SARS-CoV-2
por: Zhang, Hui, et al.
Publicado: (2021)

Role of host factors in SARS-CoV-2 entry
por: Evans, John P., et al.
Publicado: (2021)

Contribution of Syndecans to the Cellular Entry of SARS-CoV-2
por: Hudák, Anett, et al.
Publicado: (2021)

Roles of host proteases in the entry of SARS-CoV-2
por: Zabiegala, Alexandria, et al.
Publicado: (2023)

Quinolizidine Alkaloid Biosynthesis in Lupins and Prospects for Grain Quality Improvement
por: Frick, Karen M., et al.
Publicado: (2017)

Quinolizidine alkaloids are transported to seeds of bitter narrow-leafed lupin
por: Otterbach, Sophie Lisa, et al.
Publicado: (2019)

Anti-Alphaviral Alkaloids: Focus on Some Isoquinolines, Indoles and Quinolizidines
por: Sandenon Seteyen, Anne-Laure, et al.
Publicado: (2022)

Umbelliferone and eriodictyol suppress the cellular entry of SARS-CoV-2
por: Cheng, Fang-Ju, et al.
Publicado: (2023)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
por: He, Ming-Feng, et al.
Publicado: (2022)

Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells
por: Hattori, Takanari, et al.
Publicado: (2022)

Inhibitors of SARS-CoV entry – Identification using an internally-controlled dual envelope pseudovirion assay
por: Zhou, Yanchen, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vkn4pcvqv328rnti8u1qc4nu2l